Osteogenesis Imperfecta Clinical Trial
Official title:
Calcium Intake Improvement After Nutritional Intervention in Pediatric Patients With Osteogenesis Imperfecta
BACKGROUND: In several bone disorders, adequate calcium intake is a coadjuvant intervention to regular treatment. Osteogenesis imperfecta (OI) is a collagen disorder with a range of symptoms, ranging from fractures to minimum trauma, and is typically treated with bisphosphonates. This study aims evaluate the impact of a nutritional intervention (NI) on dietary calcium intake, bone mineral density (BMD)in pediatric patients with OI. METHODS: Interventional cohort study was designed with a NI. Dietary calcium intake, anthropometry and clinical feature was assessed at baseline including anthropometry, basal metabolic rate (BMR), BMD, Food guidance form was developed and sent to patients by mail. After 12 months, patients' clinical features were reassessed and compared with baseline data. RESULTS: Fifty-two children and adolescents were enrolled. A significant increase in total calcium intake (g), the percentage of adequate calcium intake (%), number of cups of milk ingested, were observed after NI. Was detected a positive correlation between the variation of BMD and milk consumption in patients treated with bisphosphonate. CONCLUSION: Was observed an increase in calcium intake in patients with OI. This finding demonstrates the importance of nutrition therapy as part of a multidisciplinary treatment approach for bone health.
Nutrition Intervention NI was performed at three nutritional visits (baseline, 6 and 12
months). Clinical features were evaluated at baseline, including anthropometric measurements,
basal metabolic rate (BMR), BMD An indirect calorimetry test was performed to estimate the
BMR of each participant. Dietary intake was assessed using daily food intake report completed
by participants on three non-consecutive days. The frequency of consumption and amount of
calcium intake were evaluated using a food frequency questionaire (FFQ) with emphasis on
foods rich in calcium. Based on these data, the nutritional needs for each subject were
calculated, and personalized food guidance (including recipes rich in calcium) was delivered
by mail.
In the second visit, at 6 months after baseline, adaptations were made to food guidance
according to the needs of each patient, doubts about feeding were clarified and the
importance of a diet rich in calcium was reinforced.
On the third visit, at 12 months after baseline, dietary calcium intake, anthropometric
measurements, , BMD were re-evaluated.
Calcium Intake Calcium intake was assessed using an FFQ adapted to calcium intake applied
before and after the NI. In the present study, the focus was on the consumption of foods high
in calcium, such as milk, yogurt, and cheese. To establish the percentage of the adequacy of
intake, the values obtained from the FFQ were compared with the Estimated Average Requirement
(EAD) and Recommended Dietary Allowances (RDA).
The FFQ for calcium intake was composed of milk (1 cup = 175 ml), 1 yogurt (120 ml), and
cheese (1 medium slice = 30 g). These foods were classified according to the consumer (as D,
daily; W, weekly, and M, monthly) and indicating the number of times (1 to 10) and the size
of the corresponding portion, if greater, equal or less than the given portion (according to
a poster with color photos to illustrate the portion size of each food source of calcium).
Consumption of glasses of milk and soda were also evaluated according to quantity and
frequency (For milk, 0 = does not consume, 1 = consume < 1 cup per day, 2 = consume 1 to 2
cups/day, and 3 = consume 3 or more cups of milk/day; for soda, 1 = consume daily, 2 =
consume only on weekends or 2 times/week, 3 = consumes less than 1 day/week, and 4 = does not
consume).
Clinical Data Clinical data were obtained during the enrollment and included age, gender, OI
type, use of bisphosphonates, and calcium intake.
Anthropometric Data and Basal Metabolic Rate Anthropometric measurements (weight and height)
were measured and evaluated according to the z-score proposed by the World Health
Organization WHO. The length was measured in the supine position in children smaller than 1 m
and children could not remain in the standing position. Patients over 1.04 m and unable to
remain standing were measured in the supine position. BMI was calculated according to the
WHO. The BMR was evaluated through indirect calorimetry and the data was published
previously.
Bone Mineral Density BMD was determined before and after the intervention using Dual Energy
X-Ray Absorptiometry (DEXA) on a Lunar DXA (GE Healthcare, San Francisco, USA). Bone mineral
content (BMC) (g), lumbar spine BMD (L1-L4), and total body BMC (TB) were calculated and
expressed as z-scores.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03557567 -
NGS Strategy Effectiveness in Molecular Diagnosis
|
||
Not yet recruiting |
NCT05559801 -
Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02531087 -
Urinary Biomarkers of OI Pathobiology
|
||
Completed |
NCT01713231 -
Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta
|
Phase 4 | |
Completed |
NCT00655681 -
Prevention of Post Operative Bone Loss in Children
|
N/A | |
Recruiting |
NCT06065111 -
Study of Osteogenesis Imperfecta Tendon
|
||
Withdrawn |
NCT03216486 -
An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
|
Phase 2 | |
Recruiting |
NCT06086613 -
A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04009733 -
Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study
|
N/A | |
Completed |
NCT04231916 -
High Resolution Thermal Imaging to Identify Vertebral Fractures in Children and Young People With Osteogenesis Imperfecta
|
N/A | |
Active, not recruiting |
NCT02814591 -
Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spectroscopy
|
||
Completed |
NCT00982124 -
An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta
|
Phase 3 | |
Completed |
NCT00001305 -
Growth Hormone Therapy in Osteogenesis Imperfecta
|
Phase 3 | |
Completed |
NCT04119388 -
Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta
|
N/A | |
Terminated |
NCT01679080 -
The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
|
Phase 2 | |
Completed |
NCT00106028 -
Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
|
Phase 3 | |
Recruiting |
NCT04152551 -
Effects of Bisphosphonates on OI-Related Hearing Loss
|
Phase 4 | |
Completed |
NCT00705120 -
Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
|
Phase 1 | |
Recruiting |
NCT04169568 -
Osteogenesis Imperfecta Blood Pressure Study
|
||
Completed |
NCT03064074 -
Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta
|
Phase 1 |